MONARCH 2 NCT02107703 was a randomized, placebo controlled, multi center study conducted in women with HR positive, HER2 negative metastatic breast cancer with disease progression following endocrine therapy treated with fulvestrant plus abemaciclib versus fulvestrant plus placebo stromectol online pharmacy
Bookmarks